The Human Immunology Core will gradually reopen to non-COVID-19 projects starting on June 8, 2020. Projects will be prioritized by the HIC in accordance with the Penn Research Resumption Strategy Master Plan. Please email Ling Zhao (firstname.lastname@example.org) with queries about prioritization of projects involving sample processing or cellular immunology assays, or Nina Luning Prak (email@example.com) about prioritization of projects involving molecular immunology.
Operational updates may change based on PSOM policy. Please check this site often for possible updates. We thank you for your patience and flexibility.
During research resumption Phase 1, sample processing cut-off times will be strictly observed:
Email Ling (firstname.lastname@example.org) for additional policies and specific directions.
If you have an existing or new project involving a cellular immunology assay (digital ELISA, Luminex, etc.) please contact Ling Zhao (email@example.com) for policies and next steps.
If you have an existing or new project involving a molecular immunology assay (immune receptor sequencing and analysis, etc.) please contact Wenzhao Meng (firstname.lastname@example.org) for policies and next steps.
Primary cell ordering will resume on June 8 with one donor on Tuesday and one on Thursday every week. Specific policies and directions for pickup are provided when you click to order cells. Please contact email@example.com with questions.
The Human Immunology Core (HIC) serves as a central facility to provide wet bench expertise for the incorporation of the newest technologies into phase I/II clinical trials using validated immunology assays, while also offering expert scientific and technical consultation to investigators conducting translational research.
Feel free to contact us with any questions.
Digital ELISA (Simoa HD-1)
For further information, please contact Ling Zhao